Contact Hours: 2.5

Max CEU Credits: 0.25

Learning Objectives:

Upon completion of the chapter, the reader will be able to:
1. Define the role of an atherosclerotic plaque, platelets, and coagulation system in an acute coronary syndrome.
2. Describe the onset, peak, and duration of elevation of troponin and creatine kinase myocardial band in acute myocardial infarction.
3. List key electrocardiographic and clinical features identifying a patient with non–ST-segment elevation acute coronary syndrome who is at high risk of myocardial infarction or death.
4. Devise a pharmacotherapy treatment plan for a patient undergoing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction given patient-specific data.
5. Devise a pharmacotherapy treatment plan for a patient with ST-segment elevation myocardial infarction given patient-specific data.
6. List the quality indicators of care for myocardial infarction and explain the rationale behind each indicator.
7. Formulate a monitoring plan for a patient with ST-segment elevation acute coronary syndrome receiving fibrinolytics, aspirin, unfractionated heparin, intravenous nitroglycerin, intravenous -blockers followed by oral -blockers, an angiotensin-converting enzyme inhibitor, and a statin.
8. Devise a pharmacotherapy treatment plan for a patient with non–ST-segment elevation acute coronary syndrome given patient-specific data.
9. Formulate a monitoring plan for a patient with non–ST-segment elevation acute coronary syndrome receiving aspirin, clopidogrel, enoxaparin, intravenous nitroglycerin, intravenous -blockers followed by oral -blockers, an angiotensin-converting enzyme inhibitor, and a statin.
10. Devise a pharmacotherapy and risk-factor modification treatment plan for secondary prevention of coronary heart disease events in a patient following myocardial infarction.

Faculty:

ACPE No:
014-999-07-017-H04

---

The University of Georgia College of Pharmacy in on probation as an accredited provider of continuing pharmacy education by the Accreditation Council for Pharmacy Education. Next scheduled review for purposes of restoring accreditation or removing accredited provider status: June 2009